Phase III STAR study of gene therapy timrepigene emparvovec did not meet primary and key secondary endpoints in patients with choroideremia

RCT in 169 adult males with this rare genetic eye disease that causes progressive vision loss and blindness failed to demonstrate increase in proportion of patients with improvement of ≥15 letters from baseline in best corrected visual acuity at 12 months post-treatment

Source:

PharmaTimes